Brenda Cooperstone, M.D.

Chief Development Officer, Pfizer Rare Disease

Dr. Cooperstone has served as a member of our board of directors since 2019. Dr. Cooperstone has held various leadership positions at Pfizer including as Senior Vice President since 2017, Chief Development Officer for Rare Disease in Global Product Development since 2016 and Head of Development for Rare Disease in Global Product Development from 2015 to 2016. Dr. Cooperstone started her career in the pharmaceutical industry at Wyeth Pharmaceuticals in 1999 and joined Pfizer in 2009.

Dr. Cooperstone earned her M.D. from McGill University, and completed her residency in pediatrics at the Montreal Children’s Hospital, her clinical fellowship in pediatric nephrology at Children’s Hospital of Philadelphia and a research fellowship at the University of Pennsylvania’s Renal Electrolyte division.